Abrdn Physical Platinum Shares ETF vs uniQure N.V. Ordinary Shares — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.56 (market cap $2.00B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Abrdn Physical Platinum Shares ETF is the larger of the two by market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 43 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PPLT | QURE | |
|---|---|---|
Market Cap | $2.00B | $1.48B |
Volume | 1,178,871 | 2,488,780 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $70.59 |
52-Week Low | $13.73 | $9.03 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.05, down 1.44% with a bearish technical outlook. Moving averages signal strong selling pressure while oscillators remain neutral. Recent news highlights platinum's underperformance in the precious metals rally, with some analysts viewing it as a potential catch-up trade opportunity despite current bearish technicals.
The ETF faces headwinds from platinum's term structure in contango, suggesting adequate supply. Historical seasonality offers some counterpoint to the bearish outlook. Investment opportunity exists if platinum catches up to gold and silver's recent rally, though supply dynamics and technical weakness present near-term risks.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →